August 2024: Medical professionals have initiated clinical trials for the first-ever mRNA lung cancer vaccine, which has been praised by specialists for its revolutionary ability to potentially rescue...
August 2024: The Food and Drug Administration (FDA) has granted approval for the use of lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, I...
August 2024: The Food and Drug Administration has granted approval for the use of durvalumab (Imfinzi, AstraZeneca) in combination with platinum-containing chemotherapy as a neoadjuvant treatment, fol...
May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small cell lung cancer (ES-SCLC) in patients wh...
Alectinib approved in the treatment of non-small cell lung cancer The Food and Drug Administration (FDA) has approved the drug Alecensa, made by Genentech, Inc. It can be used as an extra treatment f...
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor re...
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients with locally advanced or metastatic non-s...
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small cell lung cancer (NSCLC) that had mesenc...
The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) on November 15, 2...
Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post...